Early mortality in myeloma patients treated with first-generation novel agents thalidomide, lenalidomide, bortezomib at diagnosis

Sara Bringhen, Massimo Offidani, Salvatore Palmieri, Francesco Pisani, Rita Rizzi, Stefano Spada, Andrea Evangelista, Nicola Di Renzo, Pellegrino Musto, Magda Marcatti, Roberto Vallone, Sergio Storti, Annalisa Bernardini, Riccardo Centurioni, Enrico Aitini, Angelo Palmas, Ombretta Annibali, Emanuele Angelucci, Paola Ferrando, Anna BaraldiStefano Rocco, Alessandro Andriani, Agostina Siniscalchi, Valerio De Stefano, Vittorio Meneghini, Antonio Palumbo, Sara Grammatico, Mario Boccadoro, Alessandra Larocca

Research output: Contribution to journalArticle

Abstract

Introduction: Early toxic death (≤60 days of diagnosis) in elderly multiple myeloma (MM) patients is attributable to active disease, age and co-morbidities. Rate of early toxic deaths is 10% with conventional chemotherapy mainly due to infection and renal failure. Novel agents have improved MM outcome at the expense of newer toxicity. Methods: We analyzed 1146 individual patient data to assess toxic deaths during induction treatment with first-generation novel agents thalidomide, lenalidomide, bortezomib. Results: During first-line therapy, 119/1146 patients (10%) died for any cause, and 47/1146 (4%) due to toxicity, including 12/1146 (1%) early deaths. The 24-month cumulative incidence was 4.1% without any difference between bortezomib (18/503 patients, 4%) and lenalidomide (29/643patients, 5%; p = 0.31). Toxic deaths occurred in 34/1039 (3%) patients
Original languageEnglish
Pages (from-to)27-35
Number of pages9
JournalCritical Reviews in Oncology/Hematology
Volume130
DOIs
Publication statusPublished - Oct 1 2018

Cite this

Bringhen, S., Offidani, M., Palmieri, S., Pisani, F., Rizzi, R., Spada, S., Evangelista, A., Di Renzo, N., Musto, P., Marcatti, M., Vallone, R., Storti, S., Bernardini, A., Centurioni, R., Aitini, E., Palmas, A., Annibali, O., Angelucci, E., Ferrando, P., ... Larocca, A. (2018). Early mortality in myeloma patients treated with first-generation novel agents thalidomide, lenalidomide, bortezomib at diagnosis. Critical Reviews in Oncology/Hematology, 130, 27-35. https://doi.org/10.1016/j.critrevonc.2018.07.003